Rheumatoid arthritis: RA-lowering cardiovascular risk with statins

Nature Reviews Rheumatology

Volumn 6, Issue 3, 2010, Pages 123-124

  Lee, Justin M S ^a   Choudhury, Robin P ^b  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LOW DENSITY LIPOPROTEIN; METHOTREXATE; ROSUVASTATIN;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DYSLIPIDEMIA; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; INTRAVASCULAR ULTRASOUND; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SHORT SURVEY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LIPIDS; MALE; RISK FACTORS;

EID: 77749277219     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.18     Document Type: Short Survey

References (9)

1. Toms, T. E. et al. statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial under treatment of lipid associated cardiovascular risk? Ann. Rheum. Dis. doi:10.1136/ard.2009. 115717.
2. Heart Protection study Collaborative Group. MRC/BHF Heart Protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
3. Charles-schoeman, C. et al. effects of high-dose atorvastatin on anti-inflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J. Rheumatol. 34, 1459-1464 (2007).
4. Ridker, P. M., Hennekens, C. H., Buring, J. E. & Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836-843 (2000).
5. Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).
6. szekanecz, Z., Kerekes, G. & soltesz, P. vascular effects of biologic agents in RA and spondyloarthropathies. Nat. Rev. Rheumatol. 5, 677-684 (2009).
7. McCarey, D. W. et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363, 2015-2021 (2004).
8. Colhoun, H. M. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes study (CARDs): multicentre randomised placebo-controlled trial. Lancet 364, 685-696 (2004).
9. Choudhury, R. P. & Fisher, E. A. Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arterioscler. Thromb. Vasc. Biol. 29, 983-991 (2009).